Evidence map›Paper›PMID 29688266›Full record

ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2018

Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

C T Rieger, B Liss, S Mellinghoff, D Buchheidt, O A Cornely, G Egerer, W J Heinz, M Hentrich, G Maschmeyer, K Mayer and 8 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 9 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 9 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Vaccines for preventing infections in adults with solid tumours.The Cochrane database of systematic reviews · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. SEOM-GGCC clinical guidelines for the prophylaxis of infectious diseases in patients with cancer (UPDATE 2026).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. [S1 guideline on sustainability in intensive care and emergency medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025
    Review
  19. Article
  20. Booster Vaccinations Are Required.Deutsches Arzteblatt international · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

C T RiegerHematology and Oncology Germering, Lehrpraxis der Ludwig-Maximilians-Universität, University of Munich, Munich. Electronic address: christina.rieger@med.uni-muenchen.de.
B LissDepartment of Internal Medicine, Helios University Hospital Wuppertal, Wuppertal.
S MellinghoffDepartment I of Internal Medicine, University Hospital Cologne, Cologne; CECAD Cluster of Excellence, University of Cologne, Cologne.
D BuchheidtDepartment of Internal Medicine - Hematology and Oncology, Mannheim University Hospital, University of Heidelberg, Heidelberg.
O A CornelyDepartment I of Internal Medicine, University Hospital Cologne, Cologne; CECAD Cluster of Excellence, University of Cologne, Cologne; Clinical Trials Center Cologne, ZKS Köln, University Hospital of Cologne, Cologne.
G EgererDepartment of Hematology, University Hospital Heidelberg, Heidelberg.
W J HeinzDepartment of Internal Medicine II - Hematology and Oncology, University of Würzburg, Würzburg.
M HentrichDepartment of Hematology and Oncology, Rotkreuzklinikum München, Munich.
G MaschmeyerDepartment of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam.
K MayerDepartment of Hematology and Oncology, University Hospital Bonn, Bonn.
M SandherrHematology and Oncology, Weilheim.
G SillingDepartment of Hematology and Oncology, University of Aachen, Aachen.
A UllmannDepartment of Internal Medicine II - Hematology and Oncology, University of Würzburg, Würzburg.
M J G T VehreschildDepartment of Internal Medicine, Helios University Hospital Wuppertal, Wuppertal.
M von Lilienfeld-ToalDepartment of Hematology and Oncology, Internal Medicine II, University Hospital Jena, Jena.
H H WolfDepartment of Hematology and Oncology, University Hospital Halle, Halle.
N LehnersDepartment of Hematology, University Hospital Heidelberg, Heidelberg; Max-Eder-Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO)
Heidelberg University · DEHelios Universitätsklinikum Wuppertal · DEUniversity of Cologne · DEUniversity of Würzburg · DEGerman Cancer Research Center · DEJena University Hospital · DEKlinikum Ernst von Bergmann · DELudwig-Maximilians-Universität München · DERotkreuzklinikum München · DEUniversity Hospital Bonn · DEUniversity Hospital in Halle · DE

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing currently available data and applying evidence-based medicine criteria.

Indexed as

Anti-Infective AgentsCommunicable DiseasesHematologic NeoplasmsHumansNeoplasmsPractice Guidelines as TopicPrognosisStem Cell TransplantationVaccinationAnti-Infective Agents

Identifiers

PMID29688266
PMCPMC6005139
OpenAlexW2801251447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.